Found: 54
Select item for more details and to access through your institution.
Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia.
- Published in:
- Pharmaceutics, 2022, v. 14, n. 8, p. 1676, doi. 10.3390/pharmaceutics14081676
- By:
- Publication type:
- Article
MYB-GATA1 fusion promotes basophilic leukaemia: involvement of interleukin-33 and nerve growth factor receptors.
- Published in:
- Journal of Pathology, 2017, v. 242, n. 3, p. 347, doi. 10.1002/path.4908
- By:
- Publication type:
- Article
CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia.
- Published in:
- Journal of Pathology, 2015, v. 237, n. 1, p. 14, doi. 10.1002/path.4561
- By:
- Publication type:
- Article
Vérification de méthode quantitative : la formule sanguine par cytométrie en flux, le système HematoFlow® (Beckman Coulter).
- Published in:
- Annales de Biologie Clinique, 2016, v. 74, n. 5, p. 617, doi. 10.1684/abc.2016.1181
- By:
- Publication type:
- Article
Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 4, p. 1536, doi. 10.1111/bjh.19330
- By:
- Publication type:
- Article
Treatment‐free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5‐year analysis of DASFREE.
- Published in:
- British Journal of Haematology, 2023, v. 202, n. 5, p. 942, doi. 10.1111/bjh.18883
- By:
- Publication type:
- Article
Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment‐free remission period after imatinib discontinuation: Results of the French Nilo post‐STIM study.
- Published in:
- British Journal of Haematology, 2023, v. 201, n. 6, p. 1116, doi. 10.1111/bjh.18796
- By:
- Publication type:
- Article
A single center evaluation of cost savings related to treatment‐free remission in chronic myeloid leukemia patients: the prerequisites of a pharmaco‐economy larger study.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 3, p. e97, doi. 10.1111/bjh.16511
- By:
- Publication type:
- Article
Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta‐analysis of studies over the last ten years.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 3, p. 452, doi. 10.1111/bjh.16408
- By:
- Publication type:
- Article
Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 3, p. 337, doi. 10.1111/bjh.16083
- By:
- Publication type:
- Article
How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 1, p. 24, doi. 10.1111/bjh.14973
- By:
- Publication type:
- Article
BCR::ABL1 digital PCR for treatment‐free remission prediction in chronic myeloid leukemia patients: An individual participant data meta‐analysis.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 8, p. 1632, doi. 10.1002/ajh.27359
- By:
- Publication type:
- Article
Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness.
- Published in:
- Journal of Molecular Cell Biology, 2012, v. 4, n. 4, p. 207, doi. 10.1093/jmcb/mjs010
- By:
- Publication type:
- Article
A Single Nucleotide Polymorphism in cBIM Is Associated with a Slower Achievement of Major Molecular Response in Chronic Myeloid Leukaemia Treated with Imatinib.
- Published in:
- PLoS ONE, 2013, v. 8, n. 11, p. 1, doi. 10.1371/journal.pone.0078582
- By:
- Publication type:
- Article
Variable Behavior of iPSCs Derived from CML Patients for Response to TKI and Hematopoietic Differentiation.
- Published in:
- PLoS ONE, 2013, v. 8, n. 8, p. 1, doi. 10.1371/journal.pone.0071596
- By:
- Publication type:
- Article
The Necrotic Signal Induced by Mycophenolic Acid Overcomes Apoptosis-Resistance in Tumor Cells.
- Published in:
- PLoS ONE, 2009, v. 4, n. 5, p. 1, doi. 10.1371/journal.pone.0005493
- By:
- Publication type:
- Article
Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Proteomic analysis of an imatinib-resistant K562 cell line highlights opposing roles of heat shock cognate 70 and heat shock 70 proteins in resistance.
- Published in:
- Proteomics, 2008, v. 8, n. 12, p. 2394, doi. 10.1002/pmic.200701035
- By:
- Publication type:
- Article
JAK the trigger.
- Published in:
- Oncogene, 2005, v. 24, n. 48, p. 7125, doi. 10.1038/sj.onc.1208885
- By:
- Publication type:
- Article
A genome‐scale CRISPR knock‐out screen in chronic myeloid leukemia identifies novel drug resistance mechanisms along with intrinsic apoptosis and MAPK signaling.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 18, p. 6739, doi. 10.1002/cam4.3231
- By:
- Publication type:
- Article
Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
- Published in:
- Cancer Medicine, 2019, v. 8, n. 11, p. 5173, doi. 10.1002/cam4.2410
- By:
- Publication type:
- Article
Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission.
- Published in:
- Cancer Medicine, 2019, v. 8, n. 11, p. 4976, doi. 10.1002/cam4.2371
- By:
- Publication type:
- Article
Increased liposome‐mediated gene transfer into haematopoietic cells grown in adhesion to stromal or fibroblast cell line monolayers.
- Published in:
- European Journal of Haematology, 2000, v. 64, n. 1, p. 22, doi. 10.1034/j.1600-0609.2000.80230.x
- By:
- Publication type:
- Article
Loss of mutL homolog-1 (MLH1) expression promotes acquisition of oncogenic and inhibitor-resistant point mutations in tyrosine kinases.
- Published in:
- Cellular & Molecular Life Sciences, 2016, v. 73, n. 24, p. 4739, doi. 10.1007/s00018-016-2310-2
- By:
- Publication type:
- Article
α-defensin 1-3 and α-defensin 4 as predictive markers of imatinib resistance and relapse in CML patients.
- Published in:
- Disease Markers, 2011, v. 30, n. 5, p. 221, doi. 10.1155/2011/287690
- By:
- Publication type:
- Article
DASFREE: Treatment-Free Remission (TFR) After Discontinuation of Dasatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S299, doi. 10.1016/j.clml.2019.07.253
- By:
- Publication type:
- Article
ENESTop 144-Week Update: Long-Term Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S222, doi. 10.1016/j.clml.2018.07.092
- By:
- Publication type:
- Article
Treatment-Free Remission (TFR) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DMR) Discontinuing Dasatinib (DASFREE).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S220, doi. 10.1016/j.clml.2018.07.090
- By:
- Publication type:
- Article
Long-Term Follow-Up of De Novo Chronic Phase Chronic Myelogenous Leukemia Patients on Imatinib First-Line.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S306, doi. 10.1016/j.clml.2017.07.103
- By:
- Publication type:
- Article
ENESTfreedom and ENESTop Update: Durable Treatment-Free Remission (TFR) at 96 Weeks after Nilotinib Treatment Cessation in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S314, doi. 10.1016/j.clml.2017.07.115
- By:
- Publication type:
- Article
Treatment-Free Remission (TFR) Following Frontline or Second-Line Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTfreedom and ENESTop.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S64, doi. 10.1016/j.clml.2016.07.094
- By:
- Publication type:
- Article
MiR-10a and HOXB4 are overexpressed in atypical myeloproliferative neoplasms.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Novel analytical methods to interpret large sequencing data from small sample sizes.
- Published in:
- Human Genomics, 2019, v. 13, n. 1, p. N.PAG, doi. 10.1186/s40246-019-0235-1
- By:
- Publication type:
- Article
Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia.
- Published in:
- European Journal of Clinical Investigation, 2012, v. 42, n. 9, p. 1016, doi. 10.1111/j.1365-2362.2012.02675.x
- By:
- Publication type:
- Article
What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer?
- Published in:
- 2017
- By:
- Publication type:
- journal article
ELN 2013 response status criteria: Relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 1, p. 37, doi. 10.1002/ajh.23864
- By:
- Publication type:
- Article
Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: Results of the AFR04 study.
- Published in:
- American Journal of Hematology, 2013, v. 88, n. 1, p. 1, doi. 10.1002/ajh.23330
- By:
- Publication type:
- Article
A SIN lentiviral vector containing piga cdna allows long-term phenotypic correction of CD34<sup>+</sup>-derived cells from patients with paroxysmal nocturnal hemoglobinuria
- Published in:
- Molecular Therapy, 2003, v. 7, n. 3, p. 304, doi. 10.1016/S1525-0016(03)00011-X
- By:
- Publication type:
- Article
Mycophenolic Acid Overcomes Imatinib and Nilotinib Resistance of Chronic Myeloid Leukemia Cells by Apoptosis or a Senescent-Like Cell Cycle Arrest.
- Published in:
- Leukemia Research & Treatment, 2012, p. 1, doi. 10.1155/2012/861301
- By:
- Publication type:
- Article
Diagnostic et gestion des effets secondaires pleuropulmonaires des inhibiteurs de tyrosine kinase Recommandations du Groupe français pour la leucémie myéloïde chronique.
- Published in:
- Hematologie, 2018, v. 24, n. 2, p. 134, doi. 10.1684/hma.2018.1362
- By:
- Publication type:
- Article
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia.
- Published in:
- Cancer (0008543X), 2013, v. 119, n. 24, p. 4284, doi. 10.1002/cncr.28328
- By:
- Publication type:
- Article
Bundles of Auer rods in blast cells and mature neutrophils in a non-promyelocytic acute myeloblastic leukaemia.
- Published in:
- 2008
- By:
- Publication type:
- Other
Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory.
- Published in:
- Fundamental & Clinical Pharmacology, 2013, v. 27, n. 6, p. 690, doi. 10.1111/fcp.12007
- By:
- Publication type:
- Article
Treatment-Free Remission After Second-Line Nilotinib Treatment.
- Published in:
- 2018
- By:
- Publication type:
- Letter
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
- Published in:
- Annals of Internal Medicine, 2018, v. 168, n. 7, p. 461, doi. 10.7326/M17-1094
- By:
- Publication type:
- Article